Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT

Ibrutinib, a potent and irreversible small-molecule inhibitor of both Bruton’s tyrosine kinase and interleukin-2 inducible kinase (ITK), has been used to treat relapsed/refractory chronic lymphocytic leukemia (CLL) with prolongation of progression-free and overall survival. Here, we present 27 patie...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Ryan, Christine E., Sahaf, Bita, Logan, Aaron C., O’Brien, Susan, Byrd, John C., Hillmen, Peter, Brown, Jennifer R., Dyer, Martin J. S., Mato, Anthony R., Keating, Michael J., Jaglowski, Samantha, Clow, Fong, Rezvani, Andrew R., Styles, Lori, Coutre, Steven E., Miklos, David B.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2016
Pynciau:
Clinical Trials and Observations
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5179333/
https://ncbi.nlm.nih.gov/pubmed/27802969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-06-715284
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg